Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 255 free, full-text research articles on human participants. First 3 results:

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
 

Author(s): S Ohkawa, T Okusaka, H Isayama, A Fukutomi, K Yamaguchi, M Ikeda, A Funakoshi, M Nagase, Y Hamamoto, S Nakamori, Y Tsuchiya, H Baba, H Ishii, Y Omuro, M Sho, S Matsumoto, N Yamada, H Yanagimoto, M Unno, Y Ichikawa, S Takahashi, G Watanabe, G Wakabayashi, N Egawa, M Tsuda, R Hosotani, C Hamada, I Hyodo

Journal: Br. J. Cancer. 2015 Apr;112(9):1428-34.

 

This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer.

Last Updated: 29 Apr 2015

Go To URL
Anti-tumor effect of the extract from qingyihuaji formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1.
 

Author(s): Yanli Xu, Feiye Zhu, Shan Xu, Luming Liu

Journal: J Tradit Chin Med. 2015 Feb;35(1):77-83.

 

To investigate, in terms of Notch signaling pathway, the effect on pancreatic cancer of the extract of an anti-tumor prescription--Qingyi-huaji formula (QYHJ)--from Traditional Chinese Medicine (TCM).

Last Updated: 6 Apr 2015

Go To URL
Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer.
 

Author(s): Florian Gebauer, Daniel Wicklein, Jennifer Horst, Philipp Sundermann, Hanna Maar, Thomas Streichert, Michael Tachezy, Jakob R Izbicki, Maximilian Bockhorn, Udo Schumacher

Journal:

 

Aim of this study was to assess the biological function in tumor progression and metastatic process carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 in pancreatic adenocarcinoma (PDAC).

Last Updated: 21 Nov 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 4 free, full-text review articles on human participants. First 3 results:

Involvement of substance P and the NK-1 receptor in pancreatic cancer.
 

Author(s): Miguel Muñoz, Rafael Coveñas

Journal: World J. Gastroenterol.. 2014 Mar;20(9):2321-34.

 

Pancreatic cancer is the fourth leading cause of cancer related-death for both men and women and the 1- and 5-year relative survival rates are 25% and 6%, respectively. Thus, it is urgent to investigate new antitumor drugs to improve the survival of pancreatic cancer patients. The ...

Last Updated: 7 Mar 2014

Go To URL
Significance of caveolin-1 regulators in pancreatic cancer.
 

Author(s): Tao Chen, Liang Liu, Hua-Xiang Xu, Wen-Quan Wang, Chun-Tao Wu, Wan-Tong Yao, Xian-Jun Yu

Journal: Asian Pac. J. Cancer Prev.. 2013 ;14(8):4501-7.

 

Caveolin-1 is a scaffold protein on the cell membrane. As the main component of caveolae, caveolin-1 is involved in many biological processes that include substance uptake and transmembrane signaling. Many of these processes and thus caveolin-1 contribute to cell transformation, tumorigenesis, ...

Last Updated: 2 Oct 2013

Go To URL
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
 

Author(s): M Mimeault, S K Batra

Journal: Gut. 2008 Oct;57(10):1456-68.

 

Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem ...

Last Updated: 15 Sep 2008

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
 

Status: Recruiting

Condition Summary: Metastatic Pancreatic Cancer; ERCC1

 

Last Updated: 30 Jan 2012

Go to URL
Pancreatic Cancer Early Detection Program
 

Status: Recruiting

Condition Summary: Pancreatic Cancer; Pancreas Cancer; Pancreatic Adenocarcinoma; Familial Pancreatic Cancer; BRCA 1/2; HNPCC; Lynch Syndrome; Hereditary Pancreatitis; FAMMM; Familial Atypical Multiple Mole Melanoma; Peutz Jeghers Syndrome

 

Last Updated: 30 Jul 2014

Go to URL
Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
 

Status: Recruiting

Condition Summary: Advanced Pancreatic Cancer

 

Last Updated: 12 Aug 2014

Go to URL